A Study of SNDX-5613 in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04065399 |
Recruitment Status :
Recruiting
First Posted : August 22, 2019
Last Update Posted : March 25, 2024
|
Sponsor:
Syndax Pharmaceuticals
Information provided by (Responsible Party):
Syndax Pharmaceuticals
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | December 2024 |
Estimated Study Completion Date : | December 2024 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):